



# **8<sup>TH</sup> SKELETAL ENDOCRINOLOGY MEETING**

## **3<sup>RD</sup> TRANSLATIONAL ESE BONE COURSE**

### *Scientific Preliminary Program*

*Chairpersons: J.P. Bilezikian, J. Bollerslev, E. Canalis, A. Giustina, B. Obermayer-Pietsch*

### **Friday, 7<sup>th</sup> April 2017**

**1.00-2.15pm Satellite Symposium: Osteoporotic fracture current challenges and perspectives**

*Chair: A. Giustina (I)*

The paradox of fracture increase in Italy - P Piscitelli (I)  
A new approach to fracture prevention: the Nota 79 algorithm - F. Vescini (I)  
Bisphosphonates: the challenge of adherence in real life - S. Giannini (I)  
Discussion

**2.15-3.30pm Updates on hormones and fractures**

*Chair: V. Camozzi (I), A. Giustina (I)*

Treatment of adrenal insufficiency and bone - L. De Marinis  
Acromegaly and Bone - G. Mazziotti (I)  
Teriparatide and fracture: place in guidelines and in the real life - J.P. Bilezikian (US)  
Discussion

**3.30-4.00pm Opening lecture**

*Chairs: L. Moro (I), A.J. van der Lelij (NL)*  
Genetics of osteoporosis - W. Van Hul (NL)

**4.00-5.15pm Session I: Advancements in the assessment of fracture risk**

*Chairs: I. Chiodini (I), S. Minisola (I)*  
TBS - F.M. Ulivieri (I)  
QCT, pQCT & HRpQCT - M. Bouxsein (US)  
TC Cone Beam - F. Maffezzoni (I)  
Discussion

**5.15-6.30pm Session II: Denosumab What's new**

*Chairs: B. Obermayer-Pietsch (A), L. Sinigaglia (I)*  
Bone microarchitecture - S. Ferrari (CH)  
Combination treatments - S. Polyzos (GR)  
Use in cancer-related bone disease - F. Bertoldo (I)  
Discussion

**6.30-7.00pm ESE Lecture**

*Chairs: G. Bianchi (I), J. Bollerslev (N)*  
Long-term management of osteoporosis, when and how to switch - M.C. Zillikens (NL) 30 min

**7.00-7.45pm Skeletal hot topics I**

*Chairs: S. Corbetta (I), P. D'Amelio (I)*

Prevalence of malignant neoplasia in patients with primary hyperparathyroidism – L. Roggero (I)  
Exploring epigenetic changes in human parathyroid tumors: long non-coding RNA expression profile reveals heterogeneity among human parathyroid tumors – V. André (I)  
The use of denosumab in primary hyperparathyroidism – B. Carloni (I)  
Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival – F. Saponaro (I)  
Efficacy and safety of PTH (1-34) treatment in hypoparathyroidism: a prospective observational single-centre study – M. Celico (I)

**7.45 pm Opening Ceremony and Poster Display**

**Saturday, 8<sup>th</sup> April 2017**

**8.00-8.40am Skeletal hot topics II**

*Chairs: G. Mazziotti (I), F. Vescini (I)*

Tumor-induced osteomalacia mimicking spondyloarthritis: a diagnostic challenge - V. Ravagnani (I)  
Micro-RNA signatures in healthy vitamin D deficient men before and after supplementation – V. Francic (A)  
Factor affecting fracture risk in adult-onset growth hormone-deficient patients and role of the Growth hormone receptor isoforms – S. Chiloiri (I)  
Atypical femoral fractures caused by Glucocorticoid and Bisphosphonate prolonged therapy in premenopausal women: a case report – G. Franceschet (I)  
Effects of denosumab on quantitative ultrasound and Dual-Energy X-ray absorptiometry measurements in aromatase inhibitor-treated breast cancer women – F. Bellone (I)

**8.40-9.10am Lecture**

*Chairs: G. Banfi (Mi), E. Canalis (US)*

Muscle-bone interaction: The paradigm of Duchenne's Dystrophy - P. Roschger (A)

**9.10-10.20am Session III: Hypoparathyroidism**

*Chairs: J. Bilezikian (US), C. Marcocci (I)*

Determinants of skeletal phenotype - R. Rizzoli (CH)  
Clinical practice guidelines - J. Bollerslev (N)  
Replacement therapy - L. Rejnmark (DK)  
Discussion

**10.20-11.30am Session IV: Rare bone diseases**

*Chairs: G. Arioli (I), A. Rubinacci (I)*

Hypophosphatasia - M.L. Brandi (I)  
Osteogenesis imperfecta and Ehlers Danlos Syndrome - A.M. Formenti (I), G. Mazziotti (I)  
Hajdu Cheney Syndrome - E. Canalis (US)  
Discussion

**11.30-12.40pm Session V: Vitamin D and Bone**

*Chairs: E. Ghigo (I), R. Rizzoli (CH)*

Definition, assays and variables in biochemical diagnosis of hypovitaminosis D - M. Plebani (I)  
Hypovitaminosis D skeletal phenotype - R. Bouillon (B)  
Treatment with Vitamin D - B. Obermayer-Pietsch (A)  
Discussion

**12.40-1.30pm Session VI: New horizons on anti-osteoporotic therapy**

*Chairs: A. Angeli (I), F. Gonnelli (I)*

Romosozumab – C-C.J. Glüer (Ger)  
Abaloparatide - J.P. Bilezikian (US)  
Discussion

**1.30-1.45pm Conclusive Remarks**

